Johnson & Johnson group Janssen has unveiled new data showing a 50 percent cut in the risk of disease progression or death in patients with newly diagnosed multiple myeloma given Darzalex on top of standard treatment.
New analysis of trial data on Novartis’ CAR-T therapy Kymriah presented at the 59th American Society of Hematology (ASH) annual meeting show that the drug sustained complete responses at six months in adults with a difficult to treat form of blood cancer.
Eli Lilly’s Cyramza has hit its primary goal in a late-stage study showing extended progression-free survival in patients with gastric cancer, but the drug failed to improve overall survival, a secondary endpoint.
Twenty percent of young people born in the UK at the turn of the century were obese by the age of 14, while a further 15 percent were found to be overweight, according to data from UCL’s Millennium Cohort Study
Roche unit Genentech has announced that a Phase III study assessing a combination of Tecentriq and Avastin for advanced or metastatic renal cell carcinoma achieved its co-primary endpoint of progression-free survival.